Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00806611 · ClinicalTrials.gov registry record · Phase 3

Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer

A Phase 3 study of Pancreatic Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.

Completed
Registry status
Phase 3
Development phase
438
Enrollment target
1
Study location

NCT00806611: Completed Phase 3 study of Pancreatic Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.

NCT00806611 is a Phase 3 study of Pancreatic Cancer that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 438 participants, above the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (12% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00806611, a Phase 3 study of Pancreatic Cancer, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.

COMPLETED
Registry status
Phase 3
Development phase
438 participants
Enrollment target
1
Study location

Study Summary

Determine if the addition of an intraoperative ethanol celiac plexus neurolysis (alcohol block) in patients undergoing surgical intervention for pancreatic cancer will result in a decrease in cancer associated pain

Conditions Studied

Interventions

  • PROCEDURE Alcohol Block

Study Locations (1)

Pennsylvania

  • Thomas Jefferson University - Philadelphia

Trial Details

FieldValue
Enrollment Target 438 participants
Start Date 2008-09
Est. Completion 2013-04
Phase Phase 3

What the finished NCT00806611 record still lists

NCT00806611 is an interventional study that assigns participants to a tested intervention. The registered 438 participants enrollment target is mid-sized for trials with a published cap, above the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (12% higher).

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Alcohol Block is the first listed.

NCT00806611 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00806611 about?

NCT00806611 is a clinical study titled "Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer". Determine if the addition of an intraoperative ethanol celiac plexus neurolysis (alcohol block) in patients undergoing surgical intervention for pancreatic cancer will result in a decrease in cancer associated pain

What is the current status of trial NCT00806611?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 438 participants. The study started on 2008-09. Estimated completion is 2013-04.

What conditions does trial NCT00806611 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

What interventions are being tested in trial NCT00806611?

The interventions under investigation include: Alcohol Block (PROCEDURE).

Who is sponsoring clinical trial NCT00806611?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00806611 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00806611's enrollment target sits among peer trials

438 36th of 278 higher than 243 of 278 other Pancreatic Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05711446 · 438 participants · NA

    Double Voiding and Post-transplant UTI

  • NCT05421663 · 439 participants · Phase 1

    A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

  • NCT06235151 · 439 participants · Phase 3

    Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

  • NCT05114538 · 440 participants · NA

    Improving the Part C Early Intervention Service Delivery System for Children with ASD

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00806611, the US trial registry maintained by the National Library of Medicine. NCT00806611 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.